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Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is inﬂuenced by both genetic deter-
minants and smoking.We identiﬁed genomic regions from 56 lung-tissue gene-expressionmicroarrays and used them to select 889 SNPs
to be tested for association with COPD. We genotyped SNPs in 389 severe COPD cases from the National Emphysema Treatment Trial
and 424 cigarette-smoking controls from the Normative Aging Study. A total of 71 autosomal SNPs demonstrated at least nominal signif-
icance with COPD susceptibility (p ¼ 3.4 3 106 to 0.05). These 71 SNPs were evaluated in a family-based study of 127 probands with
severe, early-onset COPD and 822 of their family members in the Boston Early-Onset COPD Study.We combined p values from the case-
control and family-based analyses, setting p¼ 5.603 105 as a conservative threshold for signiﬁcance. Three SNPs in the iron regulatory
protein 2 (IREB2) gene met this stringent threshold for signiﬁcance, and four other IREB2 SNPs demonstrated combined p < 0.02. We
demonstrated replication of association for these seven IREB2 SNPs (all p values% 0.02) in a family-based study of 3117 subjects from the
International COPD Genetics Network; combined p values across all cohorts for the main phenotype of interest ranged from 1.63 107
to 6.4 3 104. IREB2 protein and mRNA were increased in lung-tissue samples from COPD subjects in comparison to controls. In
summary, gene-expression and genetic-association results have implicated IREB2 as a COPD susceptibility gene.Introduction
Chronic obstructive pulmonary disease (OMIM 606963) is
a genetically complex human disease. The identiﬁcation of
COPD susceptibility genes in particular, and genes for
complex diseases in general, has proceeded through both
candidate-gene approaches and positional-cloning ap-
proaches, but many ﬁndings have failed subsequent repli-
cation. An important feature of COPD is that cigarette
smoking, the key environmental risk factor, can be quanti-
ﬁed and included as a covariate in genetic-association
studies.
Genome-wide association methods may uncover new
susceptibility genes for complex diseases, but multidisci-
plinary methods that include integrative genomics may
be a complementary approach to identifying previously
unreported genes for complex diseases. Integrative
genomic approaches, combining gene-expression data
from both murine lung development and human lung
tissue with human linkage and association analysis, have
been used successfully by our research group for the iden-
tiﬁcation of SERPINE2 as a putative COPD susceptibility
gene.1,2
We hypothesized that a comprehensive evaluation of
genes demonstrating altered expression patterns in lung
tissue from individuals with COPD may assist in the iden-The Amertiﬁcation of COPD genes that would not have been sus-
pected on the basis of the known pathophysiology of
COPD. We investigated this hypothesis by assessing genes
differentially expressed in lung tissue from individuals
with varying degrees of airﬂow obstruction and COPD;
we then evaluted the identiﬁed SNPs in genes and genomic
regions for association in a case-control cohort, followed
by family-based genetic-association testing in two addi-
tional, independent cohorts. Some of the data presented




The microarray methods and identiﬁcation of differentially ex-
pressed genes in human lung tissue have been published.4 In brief,
RNAwas extracted from 56 lung-tissue specimens obtained during
solitary lung-nodule resection; all tissue for the array analysis was
distant from the nodule and without histologic evidence of malig-
nancy.4 All patients provided written informed consent, under-
went preoperative spirometry, and completed a questionnaire
before surgery. Preoperative prebronchodilator lung function
measures were used for classiﬁcation of subjects, because not all
subjects had postbronchodilator values. Percentage-based pre-
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Table 1. Demographics
NETT-NAS BEOCOPD ICGN
NETT NAS Probands Relatives Probands Relatives
Subjects 389 472 127 822 1132 1985
Female 140 (35.99%) 0 95 (74.80%) 458 (55.72%) 453 (40.02%) 960 (48.36%)
Age 66.69 (5.77) 69.79 (7.53) 48.09 (4.70) 46.25 (18.75) 58.31 (5.43) 57.87 (9.42)
FEV1
a 0.81 (0.26) 3.03 (0.50) 0.65 (0.28) 2.84 (1.03) 1.12 (0.41) 2.55 (1.01)
FEV1 % predicted 28.02 (7.37) 99.96 (13.12) 21.86 (8.44) 87.22 (20.27) 36.08 (12.93) 83.13 (26.08)
FEV1/FVC
a 0.32 (0.06) 0.79 (0.05) 0.31 (0.10) 0.73 (0.13) 0.37 (0.12) 0.64 (0.14)
Pack-years of smoking 66.33 (30.38) 38.59 (26.66) 38.86 (21.87) 18.96 (25.04) 52.16 (29.14) 39.06 (25.00)
Current smokers 0 31 (6.57%) 16 (12.60%) 248 (30.17%) 369 (32.60%) 1000 (50.38%)
Values are shown as n (%) or mean (SD).
a Spirometry measures presented in the table include postbronchodilator measures for BEOCOPD and ICGN and prebronchodilator measures for NETT and NAS;
for ICGN, the ratio presented is FEV1 / Vital Capacity.calculated with Crapo equations for Whites and Hankinson equa-
tions for African Americans. Cases (n ¼ 15) were deﬁned as
subjects with FEV1< 70% predicted and FEV1/forced vital capacity
(FVC) < 0.7 (mean FEV1 of the cases was 43% predicted), and
controls (n ¼ 18) as subjects with FEV1 > 80% predicted and
FEV1/FVC> 0.7 (mean FEV1 of the controls was 101% predicted).
4
Gene expression was assessed with the Affymetrix HG-U133 Plus
2.0 array, which interrogates 54,675 probe sets covering 47,000
human transcripts.
Sixty-ﬁve probe sets were identiﬁed as signiﬁcantly differentially
expressed between cases and controls as previously described.4
After the exclusion of three X chromosome probe sets (probe set
ID nos. 1558515, 230986, and 235810), we used the location of
the remaining 62 probe sets to identify regions for linkage disequi-
librium (LD) tagging and SNP selection. The expression results for
COPD cases and controls are summarized in the original manu-
script published by Bhattacharya and colleagues4 (as an online
supplement); we have listed the probe set ID numbers used for
selection of gene regions (Tables S1 and S6, available online).
Cohorts
We used a tiered approach to identify SNPs that may be associated
with COPD in three cohorts (Table 1). Genetic-association analysis
was ﬁrst performed in a case-control cohort (National Emphysema
Treatment Trial [NETT] COPD cases and Normative Aging Study
[NAS] controls), followed by replication in the Boston Early-Onset
COPD (BEOCOPD) Study, an extended-pedigree family-based
cohort. We combined the p values from the NETT-NAS and
BEOCOPD association analyses to deﬁne genes to follow up in
a third population, a family-based cohort with a broader range
of FEV1 values (International COPD Genetics Network [ICGN])
(Figure 1). The institutional review boards (IRBs) of participating
institutions in these studies approved the study protocol.
Informed consent for use of blood samples for genetic studies
was obtained for subjects from NETT, BEOCOPD, and ICGN
studies. Anonymized data sets were used for genetic analysis of
blood samples from NAS participants.
Case-Control Cohort
NETT. The NETT was a multicenter randomized treatment trial for
investigation of outcomes of medical therapy versus lung-volume-
reduction surgery for the management of advanced COPD.5494 The American Journal of Human Genetics 85, 493–502, OctoberA subset of individuals were subsequently enrolled in the NETT
Genetics Ancillary Study and had blood samples for DNA avail-












1 gene, 7 SNPs
Figure 1. Workflow of Tiered Replication Approach: SNP Selec-
tion and Replication of SNP Associations
We performed LD tagging of 62 autosomal regions identiﬁed by
microarray analysis on human lung tissue. LD tagging of the
regions (plus or minus 5 kb from the start and stop locations)
resulted in 889 SNPs tested for association in the NETT-NAS
cohorts. We carried forward 71 SNPs associated at p % 0.050 for
attempted replication, using a family-based approach, in the
BEOCOPD cohort. Finally, we performed a gene-based replication
for IREB2 variants in the ICGN cohort, testing all seven SNPs that
were associated in the NETT-NAS cohort.9, 2009
389 non-Hispanic white cases with severe COPD. All subjects had
FEV1 of less than or equal to 45% predicted and the presence of
emphysema on high-resolution CT scan (performed at enroll-
ment).5 Cigarette-smoke exposure was quantiﬁed from responses
to questionnaire data.
NAS. We included 424 non-Hispanic white controls were from
the NAS, a longitudinal study of aging conducted by the Veterans
Administration.6 All control subjects had FEV1 measures greater
than 80% of predicted, FEV1/FVC greater than 90% of predicted,
and at least 10 pack-years of smoking. Cigarette-smoke exposure
was quantiﬁed from responses to questionnaire data.
Family-Based Cohorts
BEOCOPD. The BEOCOPD cohort is an extended-pedigree study of
genetic susceptibility to COPD; the ascertainment of probands
and the recruitment of families have been reported previously.7
In brief, probands were ascertained on the basis of the presence
of severe COPD, deﬁned as FEV1 < 40% predicted before age 53
in the absence of severe alpha-1 antitrypsin deﬁciency. All family
members were invited to participate, resulting in 949 total subjects
included from 127 families. Each subject completed a modiﬁed
version of the American Thoracic Society-Division of Lung
Diseases questionnaire.8 Most subjects completed both pre- and
postbronchodilator spirometry; postbronchodilator spirometry
was performed approximately 15 min after the administration of
albuterol. For the analysis of quantitative phenotypes, we focused
on the absolute volume results for pre- and postbronchodilator
FEV1 with covariate adjustments. Cigarette-smoke exposure was
quantiﬁed from responses to questionnaire data. Given that the
initial association step was for COPD susceptibility (presence or
absence of COPD) in the NETT-NAS case-control analysis, we
also performed an analysis of the presence or absence of moderate
to severe COPD; for this analysis, a postbronchodilator FEV1 less
Table 2. Association Results for the Top 17 Significant Autosomal










9 PTCH1 rs16909859 97244613 3.40 3 106
15 IREB2 rs2656069 76532762 1.03 3 105
15 IREB2 rs10851906 76561731 2.46 3 105
15 IREB2 rs2568494 76528019 4.40 3 105
15 SEMA6D rs7167021 45833273 1.92 3 104
1 SYDE2 rs7511739 85395045 3.15 3 104
15 SEMA6D rs17388803 45814496 3.25 3 104
15 SEMA6D rs16960030 45838944 4.58 3 104
15 IREB2 rs1964678 76541055 1.61 3 103
15 IREB2 rs965604 76576278 1.81 3 103
15 IREB2 rs13180 76576543 2.17 3 103
15 SEMA6D rs76739 45829438 2.76 3 103
15 IREB2 rs12593229 76552345 2.95 3 103
6 PHACTR2 rs9386042 144061147 3.44 3 103
3 TIGIT rs4682534 115516788 4.02 3 103
1 ARHGAP29 rs3789689 94458173 4.05 3 103
15 SEMA6D rs765 45822977 5.40 3 103The Amerthan 60% predicted in the presence of FEV1/FVC less than 90%
predicted deﬁned moderate to severe COPD.1
ICGN. ICGN was a multicenter, multinational study of COPD,
with probands ascertained on the basis of COPD as deﬁned as
postbronchodilator FEV1 < 60% predicted and FEV1/vital capacity
(VC) < 90% predicted, age between 45 and 65, R 5 pack-year
smoking history, and at least one eligible sibling with R 5 years
of smoking.2 Eligible siblings were classiﬁed as having COPD if
they had postbronchodilator FEV1 < 80% predicted and FEV1/
VC < 90% predicted. Individuals with other lung diseases, such
as lung cancer, tuberculosis, and pulmonary ﬁbrosis, as well as
subjects with severe alpha-1 antitrypsin deﬁciency, were excluded
from the study. For the analysis of quantitative phenotypes, we
focused on the absolute volume results for pre- and postbroncho-
dilator FEV1 with covariate adjustments. Cigarette-smoke expo-
sure was quantiﬁed from responses to questionnaire data.
Phenotypes and Covariates
Our tiered approach (Figure 1) included an initial assessment of
genetic association of 889 SNPs with COPD susceptibility in the
NETT-NAS case-control cohort. Our primary COPD quantitative
phenotype in both family-based cohorts was FEV1, an important
COPD intermediate phenotype that provides a quantitative assess-
mentofCOPDseverity. Becauseassociationanalysis of quantitative
traits has increased power in comparison to qualitative phenotypes
and because FEV1 is the primary measure of COPD severity, we
analyzed FEV1 in the family-based cohorts and combined the
resulting p valueswith those from the case-control association tests
in the NETT-NAS screening cohort. For all subjects, cigarette-
smoking intensity was calculated as: (number of cigarettes smoked
per day / 20) / (age stopped smoking  age started smoking). For
current smokers, the calculationof pack-yearswas the same, except
that current age was used in the denominator instead of age
stopped smoking being used. Covariates for family-based associa-
tion testingof rawFEV1values includedage,height, gender, current
smoking (yes or no), and pack-years of cigarette smoking.
SNP Selection and Genotyping
In the NETT-NAS case-control study, we genotyped 889 LD tagging
SNPs in 62 regions identiﬁed after the addition of 5 kb upstream
and downstream from the probe set location. We performed LD
tagging with the Tagger program9 to capture an r2 ofR 0.8. Non-
synonymous SNPs were also genotyped if not captured by the LD
tagging approach. Hardy-Weinberg equilibrium (HWE) was evalu-
ated in the NAS control subjects. Subsequently, 71 associated SNPs
(p % 0.050) from the NETT-NAS experiment were genotyped in
the BEOCOPD study, and seven SNPs in the Iron-Responsive
Element-Binding Protein 2 gene (IREB2 [MIM 147582]) were geno-
typed in the ICGN cohort with the Sequenom iPLEX or TaqMan
50 exonuclease assays (Applied Biosystems, Foster City, CA, USA).
All SNP locations are referenced to UCSC human genome browser
(hg18, March 2006, dbSNP build 129). Gene names provided in
Tables 2, 3, and 4, and in Tables S1, S2, S3, and S6 represent the




SNPs were analyzed for association with COPD susceptibility in
the NETT-NAS study with the use of an additive genetic model
as implemented in SAS Genetics. HWE in the control subjectsican Journal of Human Genetics 85, 493–502, October 9, 2009 495
















15 IREB2 rs2568494d 76528019 A 0.38 23 4.40 3 105 9.25 3 103 6.39 3 106
15 IREB2 rs2656069d 76532762 C 0.19 10 1.03 3 105 0.35 4.93 3 105
15 IREB2 rs10851906 76561731 G 0.18 11 2.46 3 105 0.21 6.68 3 105
6 PHACTR2 rs9386042 144061147 C 0.25 10 3.44 3 103 0.07 2.37 3 103
21 CYYR1 rs222973 26800940 T 0.33 15 0.02 0.01 2.44 3 103
14 DAAM1 rs17833769 58725214 A 0.23 10 7.32 3 103 0.08 4.97 3 103
15 SEMA6D rs76739 45829438 G 0.41 22 2.76 3 103 0.28 6.24 3 103
15 IREB2 rs1964678 76541055 A 0.35 20 1.61 3 103 0.76 9.44 3 103
15 IREB2 rs965604 76576278 G 0.35 22 1.81 3 103 0.75 0.01
15 IREB2e rs13180 76576543 C 0.36 20 2.17 3 103 0.71 0.01
15 SEMA6D rs634939 45858069 C 0.41 16 0.01 0.18 0.01
6 PHACTR2 rs9321939 144096465 C 0.20 14 0.01 0.20 0.01
Abbreviations are as follows: Chr, chromosome; MAF, minor allele frequency.
a Informative families for PBAT analysis for BEOCOPD.
b BEOCOPD p value for postbronchodilator FEV1.
c Fisher combined p value; same direction of effect for the risk alleles.
d Met Fisher combined p value threshold of < 5.60 3 105.
e Genome-wide association study data from British 1958 Birth Cohort Study for FEV1 p ¼ 3 3 102.was evaluated for each SNP via a goodness-of-ﬁt test. Association
between SNPs and COPD case-control status was evaluated with
the use of 233 contingency tables for investigation of allelic addi-
tive effects with the Cochran-Armitage trend test; 71 SNPs with an
association p value % 0.050 from the trend test were carried
forward to the next step of replication in the BEOCOPD cohort.496 The American Journal of Human Genetics 85, 493–502, OctobePedigree-Based Association Test
The quantitative phenotypes of pre- and postbronchodilator FEV1
were analyzed in the BEOCOPD and ICGN family-based studies;
qualitative phenotypes for presence or absence of COPD were
also investigated in the BEOCOPD cohort. We utilized the exten-
























15 IREB2 rs2568494 a 76528019 A 0.38 23 4.40 3 105 0.01 9.01 3 106
15 IREB2 rs2656069a 76532762 C 0.19 10 1.03 3 105 0.27 3.88 3 105
15 IREB2 rs10851906a 76561731 G 0.18 11 2.46 3 105 0.17 5.51 3 105
6 PHACTR2 rs9386042 144061147 C 0.25 10 3.44 3 103 6.22x103 2.52 3 104
15 SEMA6D rs11855291 45858167 A 0.23 13 8.28 3 103 0.08 5.39 3 103
21 CYYR1 rs222973 26800940 T 0.33 15 0.02 0.04 6.37 3 103
15 IREB2 rs965604 76576278 G 0.35 22 1.81 3 103 0.50 7.25 3 103
15 IREB2 rs1964678 76541055 A 0.35 20 1.61 3 103 0.57 7.40 3 103
15 IREB2b rs13180 76576543 C 0.36 20 2.17 3 103 0.44 7.60 3 103
1 EIF2C4 rs727005 36053923 G 0.09 10 0.04 0.02 8.02 3 103
12 AMIGO2 rs2898002 45762494 G 0.29 22 0.01 0.15 0.01
15 IREB2 rs12593229 76552345 T 0.35 21 2.95 3 103 0.55 0.01
15 SEMA6D rs76739 45829438 G 0.41 22 2.76 3 103 0.72 0.01
MAF denotes minor allele frequency.
a Met Fisher combined p value threshold of < 5.60x105.
b Genome-wide association study data from British 1958 Birth Cohort Study for FEV1 p ¼ 3x102.
c Same direction of effect for the risk alleles.r 9, 2009
analyzed pre- and postbronchodilator FEV1 in both the BEOCOPD
and the ICGN cohorts. The analyses for FEV1were adjusted for age,
height, sex, current smoking (yes or no), and pack-years of ciga-
rette smoking. Analysis results were evaluated for only those
SNPs with at least ten informative families in the BEOCOPD and
ICGN studies. All PBAT models were run under the assumption
of an additive mode of inheritance.
We used Fisher’s method for combining p values from the case-
control and family-based association tests. The direction of effect
of the risk allele in all cohorts needed to be in the same direction
to be considered acceptable for combining. For the combination of
the case-control and BEOCOPD p values, a stringent threshold of
signiﬁcance, based on a Bonferroni correction for all SNPs which
ignores LD between SNPs, was set at a combined p value less
than 5.6 3 105 (~0.05 / 889; a 4 degree of freedom [df] test).
The combination of p values from all three cohorts was a 6 df
test with the use of the Fisher method.
Evaluation of IREB2 Protein and mRNA
in Human Lung
All human lung tissues for use in the protein expression experi-
ments were obtained from either lung-transplantation explant
tissues or tissues from consenting patients undergoing thoracic
surgery. These lung sections were processed immediately after
resection, and the isolated lung tissues were snap frozen and
stored at 80C. Lung homogenates from these frozen tissues
were subjected to immunoblot analyses. Tissue from 22 COPD
subjects and 18 controls were available for IREB2 protein expres-
sion studies. We isolated mRNA from these same lung tissues
and performed RT-PCR with the use of human primers (Taqman
human Hs_00386293-m1) for IREB2; RT-PCR data are referenced
to b-glucuronidase (GusB).
IREB2 antibodies were obtained from Alpha Diagnostic Interna-
tional (San Antonio, TX, USA), and immunoblot analysis was per-
formed via standard methods. The Student’s t test was used for
statistical comparisons.
Immunohistochemistry
Frozen sections from human lung were available. Control lung
samples were obtained during lobectomy for lung nodules; lung
tissue for cases consisted of tissues from lungs explanted during
lung transplantation for COPD. Samples were hydrated and
blocked with 3%hydrogen peroxide inmethanol for 30min. After
blocking with 10% normal goat serum, tissues sections were im-
munoreacted overnight with IREB2 antibodies (Alpha Diagnostic,
no. IRP21A, or Santa Cruz, no. sc-33682; 1:100). Bound primary
antibodies were visualized with diaminobenzidine staining with
the use of ABC kits (Vector Laboratories), and nuclei were counter-
stained with hematoxylin (Sigma). Both antibodies have shown
similar potency and immunoreactivity. A probed tissue without
primary antibody served as a negative control.
Results
The relevant demographics of all three study cohorts used
in genetic association analysis are described in Table 1.
We tested 889 SNPs for association in the NETT-NAS
cohort. Of these SNPs, 17 were signiﬁcant at p % 5.0 3
103(Table 2); a total of 71 SNPs demonstrated nominal
signiﬁcance in the case-control analysis at p% 0.050 (TableThe AmerS1), with 34 SNPs signiﬁcant at p % 0.01. The 71 SNPs
signiﬁcant at p% 0.050 were carried forward for attempted
replication via a family-based association approach in the
BEOCOPD study. Of note, six SNPs were out of HWE in
the NAS controls (Table S1), but we did opt to carry forward
these SNPs for further assessment in our family-based
cohort.Association results for all 889 tested SNPs are
included in Table S6.
Family-Based Analysis
For the BEOCOPD analysis of pre- and postbronchodilator
FEV1, of the 71 SNPs tested, 43 SNPs met the threshold for
having at least ten informative families contributing to the
PBAT analysis; these data are presented in Table 3 for post-
bronchodilator FEV1 for those SNPs with combined p %
0.01 (results for pre- and postbronchodilator FEV1 with
p% 0.05 are in Tables S2 and S3). Two SNPs had p values
less than 0.05 for both pre- and postbronchodilator FEV1
(IREB2 rs2568494, CYYR1 rs222973). We combined all
p values from the BEOCOPD with the results from the
NETT-NAS analysis, using a stringent threshold value for
signiﬁcance (0.05 / 889; 5.6 3 105). With the use of
Fisher’s method, two SNPs in IREB2 met this threshold
for postbronchodilator FEV1 (rs2568494, p ¼ 6.4 3 106;
rs2656069, p ¼ 4.9 3 105) (Table 3, Table S2), and one
additional SNP in the IREB2 gene (rs10851906) met this
stringent p value threshold for prebronchodilator FEV1
(Table S3). The combined p values for association for these
three IREB2 SNPs were all less than 5.63 105 for the qual-
itative phenotype of moderate to severe COPD (Table 4).
We carried forward the three globally signiﬁcant IREB2
SNPs (rs2568494, rs2656069, and rs10851906), as well as
the four other LD tagging IREB2 SNPs signiﬁcant in
NETT-NAS analysis (rs1964678, rs12593229, rs965604,
and rs13180), to perform gene-based replication testing
in the ICGN cohort. All seven IREB2 SNPs were associated
with pre- and postbronchodilator FEV1 in the ICGN cohort
(Table 5 and Table S4). The combined p values (6 df test)
across all three cohorts ranged in magnitude from 104
to 107 (Table 5 and Table S4).
As we previously reported,4 microarray analysis used for
selecting genes of interest identiﬁed differential IREB2
expression patterns in COPD cases compared to controls.
The microarray results4 suggested decreased IREB2 expres-
sion in COPD cases. qPCR-deﬁned gene expression
patterns from this published cohort were signiﬁcantly
correlated with the array data, but they did not conﬁrm
statistically signiﬁcant differences for IREB2 expression
between cases and controls. Given our replicated genetic
association data for IREB2 SNPs, we performed additional
studies examining IREB2 protein and mRNA levels in
human COPD lung tissues to clarify the direction of
mRNA and protein levels between COPD case subjects
and control subjects. We observed signiﬁcantly higher
IREB2 protein levels in emphysematous lung tissue (n ¼
22) in comparison to controls (n¼ 18) (p< 0.01) (Figure 2).
RNA was isolated from these same lung tissues, and PCRican Journal of Human Genetics 85, 493–502, October 9, 2009 497


























rs2568494 A 0.42 A 479 1.64 3 103 4.40 3 105 9.25x103 1.64 3 107
rs2656069 C 0.19 T 386 0.02 1.03 3 105 0.35 1.03 3 105
rs1964678 A 0.35 G 484 5.84 3 103 1.61 3 103 0.76 5.94 3 104
rs12593229 T 0.35 G 481 4.68 3 103 2.95 3 103 0.87 9.21 3 104
rs10851906 G 0.19 A 384 0.02 2.46 3 105 0.21 1.65 3 105
rs965604 G 0.35 A 483 4.71 3 103 1.81 3 103 0.75 5.42 3 104
rs13180 C 0.36 T 467 5.07 3 103 2.17 3 103 0.71 6.42 3 104
MAF denotes minor allele frequency.
a Same direction of effect for the risk alleles.demonstrated increased IREB2 mRNA in cases (n ¼ 20)
versus controls (n ¼ 11) (Figure 2, p < 0.05). IREB2 protein
localized to airway epithelial cells, endothelial cells, and
smooth muscle cells in the blood vessels and to immune
cells (macrophages) in the lung (Figure 3). In the airway
epithelial cells, staining was pronounced at the cilial
surface (Figure 4).
Discussion
Integrative genomics approaches can be complementary
to genome-wide association studies for facilitating the
Figure 2. Increased IREB2 Protein and mRNA Expression in
Human COPD Lung Tissues
Human lung-tissue homogenates from control (n¼ 18) and COPD
(n ¼ 22) subjects were analyzed for IREB2 protein expression by
immunoblot analysis. Total IREB2 protein expression was normal-
ized to b-actin, and the quantiﬁed results are depicted by graph.
Data represent mean 5 SD (n ¼ 18 normal and n ¼ 22 COPD
patients), p < 0.01, comparing COPD lung tissue with normal
lung. mRNA expression was extracted from the same lung tissues
and quantiﬁed with RT-PCR (n ¼ 11 normal and n ¼ 20 COPD
patients), p < 0.05, comparing COPD lung tissue with normal
lung.498 The American Journal of Human Genetics 85, 493–502, Octobeidentiﬁcation of previously unreported candidate genes
for complex human diseases. Using a tiered integrative
genomics approach, we identiﬁed the strongest genetic
association of COPD-related phenotypes with variants in
IREB2 (chromosome 15q25.1). We have demonstrated
that IREB2 may be a COPD susceptibility gene, identiﬁed
through the integration of human lung microarray gene
expression data and replicated genetic association studies
in three cohorts. Interestingly, IREB2 falls into the nucleic
acid binding andmetabolic processGOpathways identiﬁed
in the microarray studies by Bhattacharya and colleagues.4
We subsequently went on to observe that IREB2 protein
expression was higher in the lung tissue samples from
subjects with COPD. IREB2 variants are in tight LD with
SNPs associated with nicotine addiction. However, our
data from human gene expression, genetic, and lung-tissue
studies, as well as prior studies suggesting a role for lung
iron imbalance in pulmonary inﬂammation,10,11 support
a role for IREB2 in the pathogenesis of COPD.
The region that includes IREB2 has recently been signiﬁ-
cantly associated with COPD in a genome-wide association
study12. This region on 15q, which includes several genes
with variants in tight LD, including components of the
nicotinic acetylcholine receptor, has also been identiﬁed
ingenome-wide association studies of lungcancer, apulmo-
nary disease also signiﬁcantly inﬂuenced by cigarette
smoking.13–15 Our integrative genomics and functional
results suggest that IREB2 may be at least one of the key
genes inﬂuencing COPD development in this region.
The regulation of iron uptake and iron distribution
throughout the human body is under tight homeostatic
control by iron regulatory proteins (IRPs). The protein
product of IREB2 (also known as IRP2) is an RNA binding
protein that, together with IREB1, is involved in maintain-
ing human cellular iron metabolism. The IRPs sense cyto-
solic iron levels, and in response to iron, they modulate
the expression of those proteins relevant to iron uptake,
export, and sequestration.16 In the setting of systemic
iron depletion, IRPs decrease iron storage and increaser 9, 2009
Figure 3. IREB2 Localization in Normal and Emphysematous Human Lung Tissue
(A–D) IREB2 protein expression by DBA staining (brown) and counterstaining by nuclei staining (blue). IREB2 expression in control
tissue localized to (A) bronchial epithelial cells and (B) vascular endothelial cells; IREB2 expression in emphysematous tissue localized
to (C) bronchial epithelial cells and (D) macrophages (red arrows).
(E) Negative control without primary antibody in control tissue. Magniﬁcation is 2003.iron uptake.17 Hypoxemia is a common occurrence in
COPD; important features of IREB2 are that it is suggested
to be active at lower oxygen tensions16 and has been
observed to be posttranslationally regulated by hypoxia.18
The IREB2 knockout mouse has been observed to develop
microcytic anemia and neurodegeneration; this neurode-
generation is probably due to dysregulation of iron in the
brain.19
Regional variation of iron and iron binding proteins has
been demonstrated in the lungs of smokers20. Nelson and
colleagues investigated whether concentrations of iron,
ferritin, and transferrin varied in upper versus lower lobes
of smokers. Bronchoalveolar lavage (BAL) samples from
the upper lobes of smokers had higher concentrations of
iron in comparison to the lower lobes, whereas BAL ﬂuid
levels from nonsmokers did not vary. They concluded
that the distribution of lung iron and iron binding proteins
may lead to varying burdens of oxidative injury in the lung
and may be relevant to the pathogenesis of emphysema
and lung cancer, both of which occur more commonly inThe Amerthe upper lobes of the lungs. Subsequently, this same
research group observed regional variation in alveolar
iron and IL1Beta, suggesting that the burden of iron has
an impact upon regional inﬂammation in the lung.10 We
have previously demonstrated association with xenobiotic
metabolizing enzymes with emphysema distribution in
the NETT cohort, and we speculated that there may be
gradients of gene and protein expression in the lung that
contribute to COPD. Although we did not investigate
regional differences in IREB2 expression in human lung
tissue, there was a trend for association for ﬁve IREB2
SNPs (rs1964678 p ¼ 0.05; rs2656069 p ¼ 0.07;
rs12593229, rs965604, rs13180 p ¼ 0.09) with upper lobe
percentage of emphysema in a subset of 282 NETT subjects
who had densitometric quantiﬁcation of emphysema;
there was no association with a phenotype that measured
emphysema distribution (p > 0.05, data not shown). More
research on regional distribution of IREB2 gene expression
and IREB2 protein levels in the lung is required for clariﬁ-
cation of these ﬁndings.Figure 4. IREB2 Localizes to Human
Epithelial Cell Cilial Surface
Localization of IREB2 protein expression
along the cilial border in human lung
epithelial cells from normal lung tissue
(A) 2003 magniﬁcation.
(B) Enlarged image of (A) at 4003magniﬁ-
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The only previous candidate gene association study of
IREB2 variants with human disease is for Alzheimer
disease,21 a disease associated with human aging. Features
of COPD recapitulate characteristics of the lung that may
occur with aging. Deposition and accumulation of iron is
associated with cellular senescence,22 and iron in the
lung has been noted to increase with age in humans and
rats.23 Cigarette smoking has been associated with higher
accumulated iron levels in the lung.11,24,25 Ghio and
colleagues recently demonstrated that healthy smokers
and smokers with COPD had higher concentrations of
iron in the lung and systemically, suggesting that the
disruption of iron homeostasis associated with smoking
may be one contributing factor for the development of
COPD long after smoking cessation.11 Thus, polymorphic
variation in IREB2, as a major regulator of iron homeo-
stasis, may further affect COPD when coupled with the
increased levels of iron accumulated through exposure to
cigarette smoke.
Increases in cell autophagy have been associated with
smoking-related lung injury and COPD.26 Interestingly,
we have recently observed that iron is required for autoph-
agy, as treatment with the iron chelator desferoxamine
inhibits autophagy and administering iron induces
autophagy inbothepithelial andendothelial cells (A.M.K.C.,
unpublished data). Whether an effect of IREB2 on COPD
is through regulating autophagy is speculative but an
important question that future studies should address.
Figure 5. Linkage Disequilibrium Map
for All IREB2 SNPs Genotyped in NETT-
NAS Plus Two CHRNA3 Region SNPs Previ-
ously Associated with Lung Cancer and
COPD
LDmap of the 12 SNPs genotyped in IREB2
in NETT-NAS demonstrate high LD across
the gene. Additionally, there is high LD
in the NETT-NAS cohort between the
IREB2 SNPs and two SNPs in the CHRNA3
region (rs8034191, rs1051730; association
data published by Pillai et al.12) Red corre-
sponds to r2 R 0.8. Values for D0 are
included in the text of boxes.
Lung cancer and COPD probably
share common genetic and environ-
mental susceptibility factors.27 Three
independent groups performing
genome-wide association studies have
identiﬁed the chromosome 15q25
region (that includes IREB2) as associ-
ated with lung cancer.13–15 Our inde-
pendent identiﬁcation of IREB2 via
an integrative genomics approach
suggests that thismaybe an important
region for consideration with regard
to combined susceptibility to COPD
and lung cancer. In our study, the
two IREB2 SNPs identiﬁed in the asso-
ciated region in the lung cancer genome-wide association
study by Hung and colleagues15 (rs17484235 and
rs2656052) were associated with COPD case-control status
(p ¼ 1.16 3 103, 1.81 3 105 respectively) in NETT-NAS
and with postbronchodilator FEV1 (all p < 0.01) in our
BEOCOPD family-based cohort, for combined p values
that range in magnitude from 104 to 106 for these SNPs
(Table S5). Thus, IREB2 might be a gene relevant to
combined susceptibility to COPD and lung cancer, or this
gene might be independently associated with smoking
behavior (althoughwe did not detect an independent asso-
ciation for these SNPs with pack-years of cigarette smoking;
data not shown). Alternatively, our association ﬁndings in
IREB2 may be the result of high LD with SNPs in the
CHRNA3/5 gene cluster (Figure 5), and key functional vari-
ants may actually be in the CHRNA3/5 gene cluster.
However, the fact that we independently identiﬁed the
IREB2 region andnot theCHRNA3/5 regionvia gene expres-
sion analysis, together with the functional studies of IREB2
in human lung tissue, suggest that IREB2 may harbor key
functional variation, either in addition to or instead of the
CHRNA3/5 gene cluster. The identiﬁcation of functional
variants will be required for clariﬁcation of these issues.
After identiﬁcation of the IREB2 gene as a candidate via
gene expression studies, we observed association in three
cohorts, with a combined p value threshold meeting a
conservative threshold of at least 105. Limitations of our
study included the fact that genes were identiﬁed through500 The American Journal of Human Genetics 85, 493–502, October 9, 2009
an expression data set of lung nodule resections, and this
panel of genes may pick up signal relevant to lung
neoplastic changes. However, a recent paper demonstrated
increased mRNA of CHRNA5 but no change in IREB2
mRNA in lung adenocarcinomas, supporting the idea
that our ﬁnding is independent of the gene expression
patterns of the nodule tissue itself.28 Also of note is that
the microarray data for the discovery phase (Bhattacharya
et al.4) did not validate the direction of differential expres-
sion of IREB2 in the COPD cases versus controls, but the
mRNA and protein data that we present (Figure 2) suggest
an increase in IREB2 in subjects with COPD in comparison
to controls. Of note, none of the subjects in the COPD
genetic association study cohorts had known cancer, and
the fact that our ﬁndings replicated for key intermediate
COPD phenotypes is crucial. We do not know the IREB2
genotypes of the subjects from the microarray study; addi-
tionally, microarray data were considered from a small
number of subjects that ﬁt into stringent categories for
COPD case (n ¼ 15) versus control (n ¼ 18) status.4 An
additional consideration includes the differences in
phenotypes used for gene selection (case-control status)
versus replication of results (FEV1 for the family-based
cohorts). The mean FEV1 for the cases in NETT and the
BEOCOPD probands is not statistically different (p >
0.05); also, our ﬁndings for a qualitative phenotype associ-
ation (for presence or absence ofmoderate to severe COPD)
in BEOCOPD still identify IREB2 as the most highly associ-
ated gene for further investigation (p ¼ 9.0 3 106; Table
4). Quantitative traits have increased power in comparison
to qualitative traits, so we opted for attempted replication
for FEV1 in our second family-based cohort, given the
broader range of FEV1 in ICGN that captures a span of
COPD severity. The functional relevance of this association
study and true functional variants in IREB2, if they exist,
are yet to be deﬁned. However, the rs13180 SNP was
signiﬁcantly associated in the NETT-NAS case-control
status and the ICGN analyses for FEV1. This SNP is reported
to be in complete LD with a functional promoter SNP
(rs2656070) that disrupts SP1 and AP1 binding sites21.
Although the rs13180 association did not replicate in our
BEOCOPD cohort, the combined p value across all three
studies was robust and in the same direction. This SNP
also has a nominal p value for association to the FEV1
phenotype in the British Birth Cohort, a genome-wide
association data set (public access).Our ﬁndings may be
due to spurious association, but independent replication
in multiple cohorts suggests otherwise. We have demon-
strated association with SNP variants in two family-based
studies, suggesting that the role for potential population
stratiﬁcation is limited.
In conclusion, using an integrative genomics approach,
we have identiﬁed IREB2 as a potential gene for COPD
susceptibility. This approach has highlighted not only
the iron regulation pathways as potentially important to
COPD, but also the complementary role of integrative
genomics with genome-wide association studies. The iden-The Amertiﬁcation of IREB2 variants associated with COPD in a
region associated with lung cancer suggests the potential
for overlapping genetic determinants of these two
smoking-related diseases. A role for IREB2 in the lung
may be through inﬂuences on lung iron stores and subse-
quent oxidative stress or alterations in autophagy; these
pathways need to be fully investigated in both animal
models and human cohorts.
Supplemental Data
Supplemental Data include six tables and can be found with this
article online at http://www.cell.com/AJHG/.
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